Lastly, CC-220, a novel CM that targets IKZF1 and IKZF3 for degradation much more effectively than does LEN or POM, retained strong antitumor activity at clinically achievable concentrations (Schafer et al., 2018) in UBE2G1-deficient myeloma cells, suggesting that human patients with resistance to CM drugs owing to diminished UBE2G1 function may be responsive to next-generation CMs that possess higher efficiency and/or potency for degrading the same target protein. The gene discussed is UBE2G1; the disease is plasma cell myeloma.